4-AcO-MET (4-acetoxy-N-methyl-N-ethyltryptamine) is a synthetic psychedelic tryptamine belonging to the acetylated psilocybin analog family. It functions as a prodrug that is rapidly hydrolyzed by serum esterases to 4-HO-MET (4-hydroxy-MET, metocin), the presumed primary active form. Structurally, 4-AcO-MET is the N-methyl/N-ethyl analog of psilocybin — occupying a position on the tryptamine substitution spectrum between 4-AcO-DMT (dimethyl) and 4-AcO-DET (diethyl).
Community reports characterize 4-AcO-MET as a distinctly visual and aesthetic tryptamine with a character somewhat lighter and more manageable than 4-AcO-DMT at comparable doses. Users frequently describe vivid, colorful open-eye visuals, a euphoric emotional baseline, and music enhancement that is particularly pronounced. Reddit users have described the experience as combining some of the warmth and openness of the broader 4-AcO compound family with a somewhat playful character. The combination with dissociatives such as O-PCE has been documented in community trip reports, though such combinations carry additional risk.
The compound occupies a legal gray zone in most jurisdictions and circulates primarily through the research chemical market. Human pharmacokinetic data is essentially absent from the peer-reviewed literature, and the compound's safety profile is inferred from structural analogy to psilocybin and community-accumulated experience rather than formal clinical study.
Safety at a Glance
High Risk- Threshold: 5 mg | Low: 10–15 mg | Common: 15–25 mg | Strong: 25–40 mg
- Use a milligram-accurate scale. Powder doses cannot be reliably estimated by eye or volume.
- Toxicity: Overview No formal toxicological studies specific to 4-AcO-MET have been conducted in humans. Its toxicity profile is...
- Overdose risk: Fatal overdose from 4-AcO-MET alone, at doses within the typical recreational range, is extremely...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 6 hrsHow It Feels
The onset of 4-AcO-MET is brisk and cheerful by psychedelic standards. Within fifteen to twenty-five minutes of ingestion, a wave of warmth and tingling washes upward from the stomach through the chest and into the face. Mild nausea may flicker briefly but rarely lingers. Almost immediately, color saturation begins to climb — the world becomes a more vivid version of itself, as though someone has adjusted the hue and brightness controls on reality. Greens become electric, blues deepen to sapphire, and every surface seems to glow with an inner luminescence. There is an early burst of euphoria, a buoyant lightness that lifts mood and loosens the muscles.
The come-up accelerates rapidly, reaching full intensity within sixty to ninety minutes. Visuals are the headline act: surfaces flow and morph with intricate, colorful geometry that has a distinctly playful character. Patterns tend toward the ornate and organic — swirling Art Nouveau flourishes, flowing paisleys, and kaleidoscopic mandalas that shift in real time. Colors bleed and merge in ways that feel celebratory rather than disorienting. Open-eye visuals are vivid enough to be captivating but rarely so overwhelming that functional perception is compromised. Closed-eye visuals are extraordinary — vast, luminous landscapes of impossible color and geometric complexity. Music is deeply enhanced, each note arriving with emotional weight and visual accompaniment.
The headspace of 4-AcO-MET is remarkably clear and manageable compared to many tryptamines. Thought flows freely and creatively without the heavy introspective undertow of psilocin or the looping tangentiality of LSD. Conversations remain accessible, humor is amplified, and there is a persistent sense of delight that pervades the experience. The body feels good — warm, relaxed, and gently energized. Touch is subtly enhanced, and there is a mild empathogenic quality that makes social interaction feel easy and rewarding.
The peak lasts roughly two hours before beginning a smooth, comfortable descent. The vivid geometry softens to a gentle shimmer, the colors gradually return toward their natural values, and the euphoria settles into a contented calm. The total duration is typically four to five hours — shorter than most classical psychedelics — and the comedown leaves behind a warm afterglow of heightened color perception and quiet happiness. Sleep comes relatively easily afterward, often accompanied by vivid, pleasant dreams.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(16)
- Brain zaps— Brain zaps are sudden, brief, electrical shock-like sensations that originate in the head and someti...
- Changes in felt bodily form— Changes in felt bodily form is the experience of one's body feeling as though it has altered its phy...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Runny nose— Excessive nasal discharge commonly occurring during opioid withdrawal or from nasal irritation cause...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...
Cognitive & Perceptual Effects
Visual(15)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Environmental patterning— A visual effect in which existing textures and surfaces — carpets, clouds, foliage, walls — spontane...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(19)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Autonomous voice communication— Autonomous voice communication is the experience of hearing and engaging in conversation with one or...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Decision-making impairment— Reduced ability to evaluate risks, weigh options, and make sound judgments, particularly insidious b...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(2)
- Olfactory hallucination— Olfactory hallucinations (phantosmia) involve the perception of convincing phantom smells — pleasant...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Perception of interdependent opposites— Perception of interdependent opposites is the profound, felt realization that reality is structured ...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Prodrug Mechanism
4-AcO-MET is believed to be rapidly converted to 4-HO-MET (metocin) following ingestion, primarily through esterase-mediated hydrolysis of the acetyl group. This conversion likely occurs both in the gastrointestinal tract and in the systemic circulation. The acetyl moiety serves principally to increase lipophilicity and improve absorption across biological membranes, potentially improving bioavailability compared to the free phenol form.
Whether the intact acetylated compound has independent pharmacological activity at central receptors remains unclear; the available evidence suggests that the primary psychoactive effects are mediated by 4-HO-MET.
Receptor Pharmacology
4-HO-MET (metocin) acts as a partial agonist at serotonin 5-HT2A receptors — the canonical molecular target underlying the classical psychedelic effect class. Like psilocin and other 4-hydroxy tryptamines, it also binds with varying affinity to 5-HT2C, 5-HT1A, and other serotonin receptor subtypes. The contribution of these additional targets to the subjective experience is not fully characterized.
The biased agonism at 5-HT2A receptors — preferential activation of certain intracellular signaling pathways over others — is shared across the psychedelic tryptamine and phenethylamine families and is believed to underlie their class-defining effects on perception and cognition.
Pharmacokinetics
Onset following oral administration: 30–75 minutes. Peak effects: 2–3 hours. Total duration: 4–6 hours. Like other 4-AcO compounds, the acetylation likely shifts the pharmacokinetic profile slightly relative to the free 4-HO compound. No formal human pharmacokinetic data exists.
Tolerance
Rapid functional tolerance develops within 24–48 hours. Complete cross-tolerance with other 5-HT2A agonist psychedelics (psilocybin, 4-AcO-DMT, LSD). Recovery over approximately 5–7 days.
Detection Methods
Urine Detection
4-AcO-MET is not targeted by standard immunoassay-based urine drug screens. As a prodrug, 4-AcO-MET is rapidly hydrolyzed in vivo to its corresponding 4-HO (psilocin-type) metabolite, and it is primarily this metabolite that would be detected in biological specimens. Specialized LC-MS/MS methods can detect 4-substituted tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The detection window is relatively short compared to many other drug classes due to the rapid hepatic metabolism and renal clearance of tryptamine compounds. Psilocin (4-HO-DMT) is the most commonly targeted analyte in specialized tryptamine panels, and structural analogs may or may not be captured depending on the specific method.
Blood and Serum Detection
Blood detection windows for 4-AcO-MET are short, typically 4 to 12 hours after oral ingestion. Peak plasma concentrations of the active metabolite occur within 1 to 2 hours. The rapid first-pass metabolism means that parent compound concentrations in blood are often negligible for 4-AcO prodrugs, while 4-HO compounds themselves are measured directly. LC-MS/MS is required for reliable serum detection at the low concentrations involved.
Standard Drug Panel Inclusion
4-AcO-MET is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for any of the standard panel analytes (amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, benzodiazepines, or barbiturates). Detection requires a specific request for tryptamine or novel psychoactive substance testing at a reference laboratory. Some extended forensic panels include psilocin, which may capture certain 4-substituted tryptamines, but this coverage is not guaranteed for all structural variants.
Confirmatory Methods
Confirmatory identification of 4-AcO-MET relies on LC-MS/MS with reference standards specific to the compound or its expected metabolites. GC-MS can also be used following appropriate derivatization. Immunoassay-based methods for psilocybin and psilocin exist but show variable cross-reactivity with structural analogs and are not considered reliable for novel 4-substituted tryptamines. Reference laboratories specializing in novel psychoactive substances offer the most comprehensive detection capabilities.
Reagent Testing (Harm Reduction)
The Ehrlich reagent is the primary harm reduction tool for 4-AcO-MET. A sample placed on the reagent should produce a purple to violet color change, confirming the presence of an indole ring system characteristic of tryptamines. This reaction is shared with LSD, psilocybin, DMT, and all indole-containing compounds, so it confirms the general class but not the specific identity. The Hofmann reagent provides a confirmatory blue to violet reaction for tryptamines. The Marquis reagent typically shows no reaction or a dark brown discoloration with 4-substituted tryptamines. A positive Ehrlich result significantly reduces the probability that the substance is a dangerous substitute such as an NBOMe compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Synthesis and Documentation
4-AcO-MET was first described in the same 1963 Sandoz patent by Albert Hofmann and Franz Troxler that introduced the broader class of 4-acetoxy tryptamine esters. The patent systematically enumerated acetylated derivatives of psilocin, including acetylated versions of the MET, DET, DiPT, and other N-alkyl tryptamines.
Research Chemical Emergence
The compound entered the research chemical market in the 2000s alongside the broader 4-AcO family, facilitated by growing online harm reduction communities, Alexander Shulgin's documentation of tryptamine pharmacology, and the legal gray zone occupied by compounds not explicitly scheduled under the Controlled Substances Act or UN conventions.
Community Development
4-AcO-MET has accumulated a modest but growing body of community experience documentation. It is generally considered intermediate in the 4-AcO family — less frequently encountered than 4-AcO-DMT, but with a distinct enough character that experienced tryptamine users seek it out specifically for its visual and aesthetic qualities. The combination with dissociatives — documented in Reddit reports — represents one of the more frequently discussed uses in the community.
Legal Status
Like most 4-AcO compounds, the legal status of 4-AcO-MET varies by jurisdiction and is frequently ambiguous. In the United States, while not explicitly Schedule I, it is potentially subject to prosecution under the Federal Analogue Act. Several European countries have specifically scheduled it. The legal landscape continues to evolve.
Harm Reduction
Source and Test
4-AcO-MET is a research chemical with no pharmaceutical supply chain. Test all samples with an Ehrlich reagent (positive for indole tryptamines: purple/violet color). A negative Ehrlich result indicates an absence of indole alkaloids and suggests the sample is not what it purports to be.
Dosing
- Threshold: 5 mg |Low: 10–15 mg |Common: 15–25 mg |Strong: 25–40 mg
- Use a milligram-accurate scale. Powder doses cannot be reliably estimated by eye or volume.
- Start at 10–15 mg for first experiences. Individual sensitivity varies substantially.
- Do not redose until at least 2 hours have passed — onset can be delayed on a full stomach.
Combinations to Avoid
Community reports of 4-AcO-MET combined with dissociatives like O-PCE document experiences ranging from remarkable to deeply overwhelming. The combination dramatically increases cognitive disorganization and dissociation, making the "trip sitter" function and post-experience integration more critical. If exploring combinations, do so with extreme caution at low doses of both components.
Set and Setting
Identical to all serotonergic psychedelics: stable mindset, familiar comfortable environment, sober trip sitter ideally present, no pending obligations or high-stakes situations. The enhanced visual and aesthetic character of 4-AcO-MET makes it particularly sensitive to environmental inputs — invest in quality music, lighting, and surroundings.
If Needed: Abort
Benzodiazepines (diazepam 10–20 mg) safely and reliably reduce 4-AcO-MET intensity. This is the harm reduction standard for overwhelming experiences and carries no dangerous pharmacological interaction with tryptamines.
Toxicity & Safety
Overview
No formal toxicological studies specific to 4-AcO-MET have been conducted in humans. Its toxicity profile is extrapolated from structural analogy to psilocybin and 4-AcO-DMT, both of which demonstrate very low acute physiological toxicity. No documented fatalities attributable specifically to 4-AcO-MET have been identified.
Physiological Effects
Standard serotonergic sympathomimetic effects: pupil dilation, mild tachycardia, modest blood pressure elevation, nausea during onset (particularly on a full stomach). These are generally transient and self-limiting. Occasionally, nausea can progress to vomiting during the onset phase.
Psychological Risks
- Anxiety and difficult experiences — As with all psychedelic tryptamines; dose-dependent and highly context-sensitive.
- Psychosis trigger — Absolute contraindication in individuals with personal or family history of schizophrenia or psychotic disorders.
- Disinhibition and decision-making impairment — Community reports of combinations with dissociatives (O-PCE) highlight the increased cognitive impairment and unpredictability inherent in polydrug psychedelic sessions.
- HPPD — Rare but possible; the risk of persisting perceptual disturbances following any 5-HT2A agonist psychedelic should not be dismissed.
Drug Interactions
- MAOIs — Potentiation; serotonin syndrome risk; avoid.
- Lithium — Contraindicated; seizure risk.
- Dissociatives (ketamine, DCK, O-PCE) — Can profoundly intensify and destabilize the experience; significantly higher risk of overwhelming or disorienting effects. Reddit reports document such combinations going both remarkably and severely.
- Cannabis — Unpredictable intensity amplification.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 4-AcO-MET alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Germany: 4-AcO-MET is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of 4-AcO-MET are punishable as an incitement to place it on the market.
Switzerland: 4-AcO-MET is a controlled substance specifically named under Verzeichnis E.
United Kingdom: 4-AcO-MET is a Class A drug in the UK as it is an ester of the drug 4-HO-MET, which is a Class A drug as a result of the tryptamine catch-all clause.
United States: 4-AcO-MET is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
Responsible use
Research chemicals
Psychedelics
Tryptamine
4-HO-MET
4-AcO-MET (Wikipedia)
4-AcO-MET (Isomer Design)
Discussion
The Big & Dandy 4-AcO-MET Thread (Bluelight)
Experience Reports (1)
Tips (6)
Use a milligram scale to weigh 4-AcO-MET if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 4-AcO-MET and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
If you feel overwhelmed during a 4-AcO-MET experience, remember it only lasts 4-6 hours total. Change your environment, put on calming music, and practice deep breathing. Having a benzodiazepine on hand as a trip-killer provides peace of mind.
Standard dose is 20-30mg oral. If 4-AcO-MET seems to take unusually long to kick in, do not redose — it occasionally has a delayed onset of up to 90 minutes. Redosing often leads to an unexpectedly intense experience once both doses hit.
4-AcO-MET is very similar to 4-HO-MET — lightweight, visual, and recreational. When combined with dissociatives like O-PCE, users report extremely immersive experiences with enhanced visual depth and cosmic headspace.
Integration is just as important as the experience itself. After using 4-AcO-MET, take time to journal, reflect, or discuss the experience. Insights from psychedelic states can be powerful but need conscious effort to apply to daily life.
Community Discussions (2)
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 4-AcO-MET - TripSit Factsheet
TripSit factsheet for 4-AcO-MET
tripsit - 4-AcO-MET - Wikipedia
Wikipedia article on 4-AcO-MET
wikipedia